Safety and preliminary efficacy of rogaratinib in combination with atezolizumab in a phase Ib/II study (FORT-2) of first-line treatment in cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (UC) and FGFR mRNA overexpression Meeting Abstract
| Authors: | Rosenberg, J. E.; Gajate, P.; Morales-Barrera, R.; Lee, J. L.; Necchi, A.; Penel, N.; Zagonel, V.; Sierecki, M. R.; Piciu, A. M.; Ellinghaus, P.; Sweis, R. F. |
| Abstract Title: | Safety and preliminary efficacy of rogaratinib in combination with atezolizumab in a phase Ib/II study (FORT-2) of first-line treatment in cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (UC) and FGFR mRNA overexpression |
| Meeting Title: | 56th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 38 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2020 May 29-31 |
| Meeting Location: | Virtual Conference |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2020-05-20 |
| Language: | English |
| ACCESSION: | WOS:000560368302271 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2020.38.15_suppl.5014 |
| Notes: | Meeting Abstract: 5014 -- Source: Wos |
